Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO – Get Free Report)’s stock price crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.22 and traded as low as $0.1681. Northwest Biotherapeutics shares last traded at $0.1717, with a volume of 1,469,451 shares.
Northwest Biotherapeutics Price Performance
The company has a market cap of $289.84 million, a P/E ratio of -0.01 and a beta of -0.63. The company has a fifty day simple moving average of $0.20 and a 200-day simple moving average of $0.22.
About Northwest Biotherapeutics
Northwest Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of personalized dendritic cell immunotherapies for the treatment of cancer. The company’s proprietary platform harnesses patient-derived dendritic cells to present tumor-specific antigens and stimulate a targeted immune response. By tailoring each vaccine to the individual patient’s tumor profile, the approach aims to improve outcomes and reduce off-target toxicity associated with conventional therapies.
The company’s lead candidate, DCVax®-L, is designed for patients with newly diagnosed or recurrent glioblastoma multiforme (GBM) and has advanced through a global Phase III clinical trial.
Read More
- Five stocks we like better than Northwest Biotherapeutics
- AMD and Cerbras Create A New Blueprint For Hardware
- Intel Earnings Reveal Whether the Chip Selloff Created a Buy
- CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test
- Plugging In: How Kinder Morgan Powers Up Profits
Receive News & Ratings for Northwest Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Northwest Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
